S – I –R Interpretation (INT) derived from CLSI 2024 M100 S34
1 Reflects MIC of first component 2 Cefepime to zidebactam ratio (1:1) 3 Clinical and PK/PD data demonstrate colistin has limited clinical efficacy, even if an intermediate result is obtained. Alternative agents are strongly preferred. Colistin should be used in combination with one or more active antimicrobial agents. Consultation with an infectious disease specialist is recommended. 4 Based on FDA break points 5 Screen for metallo-beta-lactamase production [Rasheed et al. Emerging Infectious Diseases. 2013. 19(6):870-878] 6 Screen test for Extended-Spectrum-β-lactamase (ESBL) production (CLSI M100). Per CLSI, use of the ESBL test is limited to isolates of Klebsiella pneumoniae, K. oxytoca, Escherichia coli, and Proteus mirabilis. It should be noted that the presence of other β-lactamases (carbapenemases and/or AmpC) or porin alterations can mask the ESBL production and confound the interpretation of the ESBL screen test.
|